FindTrial
Sign In

A medical records based study for application of 18F-FDG PET/CT radiomics in prognosis assessment of lung cancer

Application of 18F-FDG PET/CT radiomics in prognosis assessment of lung cancer: a multicenter clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031155
Enrollment
Unknown
Registered
2020-03-23
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:Clinical outcome
Index test:&#32
prognosis&#32
model&#32
of&#32
lung&#32
cancer

Sponsors

Hainan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histological or cytological diagnosis of primary lung cancer; 2. First 18F-FDG PET/CT examination; 3. Without any antitumor treatment; 4. ollow-up patients with progression-free survival and overall survival.

Exclusion criteria

Exclusion criteria: 1. Other malignant mass lesions; 2. PET/CT image quality does not meet the requirements of radiomics analysis; 3. Without pathological diagnosis; 4. Died for other reasons; 5. Failure to obtain long-term follow-up results.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progression-free survival;—

Countries

China

Contacts

Public ContactYu Lijuan

Department of Nuclear Medicine, Hai'nan Cancer Hospital

yulijuan2003@126.com+86 18745739945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026